We are currently enrolling patients for treatment of NASH Fatty Liver with an oral medication (no injection or infusion). If you are interested in enrolling in this study or referring patient, please contact our research study coordinator at amizuta@stanford.edu. We will get back to you within 24 hours or sooner.

Enrolling patients for treatment of NASH Fatty Liver

Showing 1 - 2 of 2 trials

  • Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA)

    The study aims to evaluate two, orally administered, investigational agents - PF-06865571 (DGAT2 inhibitor) and the coadministration of PF-06865571 with PF-05221304 (ACC inhibitor). This study is specifically designed to evaluate the effect of a range of doses of DGAT2i alone, and DGAT2i + ACCi, on resolution of NASH or improvement in liver fibrosis, as assessed histologically (via liver biopsy).

    Now accepting new patients View Details
  • A Randomized, Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Liver-biopsy Proven NASH

    A randomized, double-blind study to assess the safety and efficacy of EDP-305 in subjects with liver-biopsy proven Non-Alcoholic Steatohepatitis (NASH)

    Now accepting new patients View Details

Akiko Mizuta
Research Coordinator
c: 408-431-7567
amizuta@stanford.edu

Jeff Mathews
Administrative Associate
650-498-6084
jsmath@stanford.edu